3D pharmacophore models for thromboxane A2 receptor antagonists

被引:2
作者
Wei, Jing [1 ]
Liu, Yixi [1 ]
Wang, Songqing [1 ]
机构
[1] Tianjin Univ, Sch Pharmaceut Sci & Technol, Tianjin Key Lab Modern Drug Delivery & High Effic, Tianjin 300072, Peoples R China
关键词
Thromboxane; Receptor; Antagonist; Pharmacophore model; HypoGen; HipHop; DIBENZOXEPIN RING-SYSTEM; SYNTHASE INHIBITORS; A2; DERIVATIVES; CYANOGUANIDINE; AGONIST;
D O I
10.1007/s00894-009-0475-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Thromboxane A(2) (TXA(2)) is an endogenous arachidonic acid derivative closely correlated to thrombosis and other cardiovascular diseases. The action of TXA(2) can be effectively inhibited with TXA2 receptor antagonists (TXRAs). Previous studies have attempted to describe the interactions between the TXA(2) receptor and its ligands, but their conclusions are still controversial. In this study, ligand-based computational drug design is used as a new and effective way to investigate the structure-activity relationship of TXRAs. Three-dimensional pharmacophore models of TXRAs were built with HypoGenRefine and HipHop modules in CATALYST software. The optimal HypoGenRefine model was developed on the basis of 25 TXRAs. It consists of two hydrophobic groups, one aromatic ring, one hydrogen-bond acceptor and four excluded volumes. The optimal HipHop model contains two hydrophobic groups and two hydrogen-bond acceptors. These models describe the key structure-activity relationship of TXRAs, can predict their activities, and can thus be used to design novel antagonists.
引用
收藏
页码:1185 / 1191
页数:7
相关论文
共 21 条
  • [1] THROMBOXANE-A2 - ITS GENERATION AND ROLE IN PLATELET ACTIVATION
    ARITA, H
    NAKANO, T
    HANASAKI, K
    [J]. PROGRESS IN LIPID RESEARCH, 1989, 28 (04) : 273 - 301
  • [2] COLLINGTON EW, 1990, ANNU REP MED CHEM, V25, P99
  • [3] AGENTS COMBINING THROMBOXANE RECEPTOR ANTAGONISM WITH THROMBOXANE SYNTHASE INHIBITION - [[[2-(1H-IMIDAZOL-1-YL)ETHYLIDENE]AMINO]OXY] ALKANOIC ACIDS
    COZZI, P
    GIORDANI, A
    MENICHINCHERI, M
    PILLAN, A
    PINCIROLI, V
    ROSSI, A
    TONANI, R
    VOLPI, D
    TAMBURIN, M
    FERRARIO, R
    FUSAR, D
    SALVATI, P
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (21) : 3588 - 3604
  • [4] FUNK CD, 1993, MOL PHARMACOL, V44, P934
  • [5] THROMBOXANE SYNTHASE INHIBITORS, THROMBOXANE RECEPTOR ANTAGONISTS AND DUAL BLOCKERS IN THROMBOTIC DISORDERS
    GRESELE, P
    DECKMYN, H
    NENCI, GG
    VERMYLEN, J
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1991, 12 (04) : 158 - 163
  • [6] GRESELE P, 1984, THROMB HAEMOSTASIS, V52, P364
  • [7] THROMBOXANE A2 RECEPTOR ANTAGONISTS
    HALL, SE
    [J]. MEDICINAL RESEARCH REVIEWS, 1991, 11 (05) : 503 - 579
  • [8] THROMBOXANE A(2) RECEPTORS
    HALUSHKA, PV
    ALLAN, CJ
    DAVISBRUNO, KL
    [J]. JOURNAL OF LIPID MEDIATORS AND CELL SIGNALLING, 1995, 12 (2-3): : 361 - 378
  • [9] Design, synthesis, and SAR study of a series of N-alkyl-N'-[2-(aryloxy)-5-nitrobenzenesulfonyl]ureas and -cyanoguanidine as selective antagonists of the TPα and TPβ Isoforms of the human thromboxane A2 receptor
    Hanson, Julien
    Dogne, Jean-Michel
    Ghiotto, Jeremie
    Moray, Anne-Lise
    Kinsella, B. Therese
    Pirotte, Bernard
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (16) : 3928 - 3936
  • [10] SYNTHESIS OF THROMBOXANE RECEPTOR ANTAGONISTS WITH BICYCLO[3.1.0]HEXANE RING-SYSTEMS
    KAMATA, S
    HAGA, N
    TSURI, T
    UCHIDA, K
    KAKUSHI, H
    ARITA, H
    HANASAKI, K
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1990, 33 (01) : 229 - 239